Hypersensitivity, Immediate Completed Phase 3 Trials for Dupilumab (DB12159)

Also known as: Type I Hypersensitivity / Immediate Hypersensitivity / Hypersensitivity type I / Hypersensitivity type I NOS / Immediate hypersensitivity reaction

IndicationStatusPhase
DBCOND0031076 (Hypersensitivity, Immediate)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03720470Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyTreatment
NCT03054428Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisTreatment